Trial Profile

A phase 2 trial of PST-101

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Mar 2026 New trial record
10 Mar 2026 According to a Piston Bio media release, based on FDA feedback from the meeting, Piston Bio plans to submit an IND for PST-101 in 2026.
10 Mar 2026 According to a Piston Bio media release, the company announced the completion of a Type B Pre-IND meeting with the Division of Psychiatry and the Division of Oncology of the U.S FDA to discuss the clinical development program for PST-101, both aligned on design of the phase II trial including endpoints, patient population, treatment duration, and dose selection. The agreed Phase 2 outcome measures include the Apathy Evaluation Scale - Clinician Version, clinician and patient global ratings.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com